This tissue culture facility has been in operation since 1973, functioning as a centralized core laboratory to provide research material to the projects of the medical oncology research program. Stock cell lines used in the various projects are maintained by the laboratory. Cell line profiles and a frozen cell inventory are also maintained. The Core has the capacity to prepare relatively large volumes of tissue culture cells for individual studies. It also may perform routine cell experiments, e.g. preparation of cell pellets after exposure of cells to different drugs or hormonal manipulations, as well as growth assays (counts or MTT assays for anchorage-dependent growth, soft agar for anchorage-independent growth). Preparation and maintenance of transfectants are also important activities of this Core. Centralization of this fully equipped laboratory operation provides: (a) optimum efficiency in management and use of time, equipment, resources and physical facilities; (b) Coordination of preparation and ordering of tissue culture supplies, with improved quality assurance of reagents; (c) Extensive inventory, continuous source, and quality control of breast tumor and other pertinent cell lines; and (d) A service for the production of tumor-bearing animals. This centralization reduces overall costs of supplies and effort required for routine maintenance and quality control of cell cultures for all Program Project investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
7P01CA030195-19
Application #
6203068
Study Section
Project Start
1999-08-31
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Barone, Ines; Brusco, Lauren; Gu, Guowei et al. (2011) Loss of Rho GDI* and resistance to tamoxifen via effects on estrogen receptor *. J Natl Cancer Inst 103:538-52
Rimawi, Mothaffar F; Wiechmann, Lisa S; Wang, Yen-Chao et al. (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351-61

Showing the most recent 10 out of 260 publications